Results of Precision Biologics Phase 2 Colorectal Cancer Study Published in Clinical Cancer Research
Precision Biologics announces that the results of the Phase II Clinical Trial using its lead...
30Apr
07Feb
Indirect mechanisms of action of a novel IgG1 monoclonal antibody, NEO-201, that enhance immune killing of tumor
NEO-201 is an IgG1 mAb targeting variants of CEACAM5/6 that demonstrates tumor sensitivity and specificity....
23Jan
Phase 1 with Expansion Cohorts in a Study of NEO-201 in Adults with Chemo-Resistant Solid tumors
This is a first-in-human phase 1 study to determine the maximum tolerated dose (MTD) and...
16Jan
The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity
The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of...
17Dec
Rationale, discovery and clinical development of NEO-201
Most monoclonal antibody cancer therapies are developed for known targets and are commercially approved for...
06Nov
SITC 2019
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...
27Oct
Immuno-Oncology Europe 2019
Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes Presented by Dr. Philip Arlen President and CEO,...
15Oct
Novel Targets Of Neoantigens In Monoclonal Antibodies
Philip M. Arlen, M.D. Summary: Target is broadly expressed in multiple solid tumors. Exhibits both ADCC and CDC...
06Aug
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION – Cambridge Healthtech Institute August 8-9, 2019
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION, PANEL DISCUSSION:...
30Apr
2019 ASCO Annual Meeting
Abstract Title: Phase 1 with expansion cohorts in a study of NEO-201 in adults with...